

Comparison of Metformin with Insulin in the Management of Gestational Diabetes

Rao Muhammad Akram Khan¹, Ayesha Mukhtar² and Anam Khawar²

ABSTRACT

Objective: Purpose of this study is to determine the efficacy of metformin as opposed to insulin in management of gestational diabetes mellitus.

Study Design: Randomized control trial.

Place and Duration of study: This study was conducted at the Gynecology and Obstetrics, Lady Wellington Hospital, Lahore from May 2016 to March 2017.

Materials and Methods: Ethical approval was obtained from Hospital Ethics Committee. Sample was calculated using non probability consecutive sampling technique. Total 770 Patients were randomly divided into two equal groups, group M (metformin) and Group I (insulin). Glycemic control, mode of delivery and associated medical complication were recognized as possible maternal outcomes while congenital anomalies (if any), macrosomia, hypoglycemia, hyperbilirubinemia were the neonatal outcomes assessed by clinical and laboratory investigations. These outcomes were subjected to statistical analysis by using computer software SPSS version 23. Percentages were calculated for dichotomous variables and range, mean and standard deviation was calculated for continuous data. Chi square and t-test were applied to compare the two groups. P value less than 0.05 was considered as significant.

Results: Overall 100% (n=770) female patients were included, in this study; divided into two equal groups 50% (n=385) in each i.e. metformin (Group M) and insulin (Group I). Significant difference was found between age (p=0.000), gravidity (p=0.012), gestational age (p=0.000), BMI in early pregnancy (p=0.000), FBS at entry (p=0.000), FBS after treatment (p=0.000), HbA1c at entry (p=0.000), HbA1c after treatment (p=0.000), in groups. Association was found between Preeclampsia (p=0.000), Pre-term birth (p=0.000), Neonatal birth weight>4 (p=0.002), neonatal hypoglycemia (p=0.000), in groups.

Conclusion: This study concludes that metformin is as much effective as insulin in management of gestational diabetes mellitus. Metformin when used securely can prove effective as it does not cause any congenital anomalies or maternal or neonatal complications. But insulin still remains the gold standard for treatment of gestational diabetes mellitus.

Key Words: Diabetes Mellitus, Gestational Diabetes, Metformin, Insulin, Pregnancy

Citation of article: Khan RMA, Mukhtar A, Khawar A. Comparison of Metformin with Insulin in the Management of Gestational Diabetes. Med Forum 2017;28(11):105-109.

INTRODUCTION

Glucose intolerance of any level with onset or first identified during the pregnancy can be called as gestational diabetes¹. Overall morbidity of gestational diabetes is increasing with passing time. According to an estimate, 1 to 14% of all the pregnancies are complicated by gestational diabetes, which of course depends upon the size of the population under study, type of classification and diagnostic tests used². Gestational diabetes is thought to have both short and

long term outcomes which affect both mother and newly born child³. Out of the complications faced by the pregnant mother most common are preeclampsia, increased risk of developing diabetes mellitus type 2 after pregnancy and cesarean section. In case of neonatal morbidities, risk of neonatal loss becomes greater; there is also risk of still birth and congenital abnormalities, all because of excess glucose transfer from mother to fetus. Macrosomia is another major complication which can lead to shoulder dystocia during transvaginal birth, presenting a risk for instrumental deliveries, C-section and neonatal hypoglycemia later⁴. Intrauterine hyperglycemic environment may cause this condition to pass on to the children of the mother who is suffering from gestational diabetes⁵. That is why the aim of management of gestational diabetes is to control the glycemic levels and hence reduce the horrible post-pregnancy outcomes⁶.

Possible treatments to reduce these complications can be enlisted as, exercise⁷, diet modifications, insulin and

¹. Department of Medicine, Mayo Hospital, Lahore.

². Department of Gynaecology, Lady Wellington Hospital, Lahore.

Correspondence: Dr. Rao Muhammad Akram Khan, Ex-House Officer, Department of Medicine, Mayo Hospital, Lahore.

Contact No: 0336-3111107

Email: raoakram007@gmail.com

oral hypoglycemic conditions. Up till now, insulin therapy has been considered as gold standard for treatment of gestational diabetes as diet modification with or without exercise is not enough to resolve this grave problem⁸. Although insulin is the treatment of choice but it does come with some side effects like weight gain, several injections per day and a risk of developing hypoglycemia⁹. So adjustments are made according to the BMI, lifestyle of the patient and blood glucose level. In other words, a detailed guidance is necessary regarding change in insulin dosages, so that self administration can be ensured to be safe. As expected, oral insulin therapy is much more satisfying and preferable in women with gestational diabetes, until its safe and effective.

Oral hypoglycemic drugs should also be considered especially in order to identify their effect on the final outcomes in both mothers and neonates. Metformin is first line of drug in the management of type 2 diabetes mellitus¹⁰ and can be considered as another possible treatment option for gestational diabetes. But studies have shown a mother to fetus transfer of almost 10 to 16% in case of metformin¹¹ which poses a great risk to both mother and the fetus as chances of adverse effects in mothers and birth defects in newborn increases significantly. This is the reason metformin has not been used widely in gestational diabetes management.

Multiple studies have been performed in past in order to determine the efficacy and safety of metformin in management of gestational diabetes but most of these studies were cross-sectional and had smaller sample size which does not sufficiently describe the effect of metformin on maternal and neonatal outcomes. Thus, in this study our aim is to compare the efficacy of metformin with insulin therapy in gestational diabetes management, in terms of maternal and neonatal outcomes. Reference for this study was taken from a recent study performed by Hesham Borg et al¹².

MATERIALS AND METHODS

The study took place in department of Gynecology and Obstetrics, Lady Wellington Hospital, Lahore, from May 2016 to August 2017. Study design is Randomized control trial. Ethical approval was obtained from Hospital Ethics Committee. Sample was calculated using non probability consecutive sampling technique, using the reference study by Hesham Borg et al. Confidence level was taken as 95% and power of study as 80% and mean and standard deviation of outcome variable postprandial blood sugar level was used to calculate the sample size. As a result 770 patients were taken as the required sample size for our study. Total no. of 770 patients was included in the study. Inclusion criteria described by Carpenter and Coustan was used to select the patients of gestational diabetes, according to which, blood glucose level must be, fasting > 95 mg/dl, at 1hr >180mg/dl, at 2h >155mg/dl and at 3h

>146mg/dl, along with hospital criteria to start insulin therapy. Those patients who were in labor, had contradiction against metformin or with fetal anomalies, preeclampsia, gestational hypertension, ruptured membranes or fetal growth restrictions were excluded from the study. Informed consent was taken from the patients before involving them into the study. Patients were randomly divided into two equal groups, group M (metformin) and Group I (insulin). Metformin was given to patients of group M as 500 mg dose/day orally in morning and increased by 500 mg per week if required. Mixed human suspension of insulin was given as 0.7 U/kg of body weight subcutaneously two times a day and was also increased as per requirement. Weekly examination of the patients was scheduled which involved, history taking, general physical examination and fasting blood sugar and postprandial blood sugar (glycemic profile). Weekly visit involved dose adjustments if required and provision of standard obstetric care. Basic facilities were provided at antenatal clinic level including ultrasound examination. Ultrasound examination was performed at first visit and then at 16 to 19 weeks (2nd visit) and then monthly after 28 weeks of gestation. Glycemic control, mode of delivery and associated medical complication were recognized as possible maternal outcomes while congenital anomalies (if any), macrosomia, hypoglycemia, hyperbilirubinemia were the neonatal outcomes assessed by clinical and laboratory investigations. These outcomes were subjected to statistical analysis by using computer software SPSS version 23. Percentages were calculated for dichotomous variables and range, mean and standard deviation was calculated for continuous data. Chi square and t-test were applied to compare the two groups. P value less than 0.05 was considered as significant.

RESULTS

Overall 100% (n=770) female patients were included, in this study; divided into two equal groups 50% (n=385) in each i.e. metformin (Group M) and insulin (Group I). The mean age, gravidity, parity, gestational age, BMI in early pregnancy and BMI during treatment of the patients of group M was 24.92 ± 2.57 years, 2.57 ± 1.17 , 1.48 ± 0.66 , 27.94 ± 2.57 weeks, 22.08 ± 2.98 kg/m² and 31.88 ± 2.26 kg/m² respectively. While, the mean age, gravidity, parity, gestational age, BMI in early pregnancy and BMI during treatment of the patients of group I was 28.01 ± 2.53 years, 2.35 ± 1.19 , 1.41 ± 1.06 , 29.92 ± 2.27 weeks, 23.82 ± 2.81 kg/m² and 32.05 ± 1.89 kg/m² respectively. (Table1).

The Mean \pm S.D FBS at entry, FBS after treatment, 2hPPBS at entry, 2hPPBS after treatment, HbA1c at entry and HbA1c after treatment of the patients of group M was 130.06 ± 10.34 mg/dl, 82.28 ± 5.51 mg/dl, 175.18 ± 7.89 mg/dl, 111.94 ± 7.02 mg/dl, 5.73 ± 0.54

mg/dl and 5.08 ± 0.42 mg/dl respectively. While, the Mean \pm S.D FBS at entry, FBS after treatment, 2hPPBS at entry, 2hPPBS after treatment, HbA1c at entry and HbA1c after treatment of the patients of group I was 122.37 ± 9.94 mg/dl, 76.88 ± 7.75 mg/dl, 174.46 ± 6.02 mg/dl, 112.34 ± 5.02 mg/dl, 6.15 ± 0.59 mg/dl and 5.71 ± 0.49 mg/dl respectively.

Table No.1: Demographic Variables

Variable	Metformin n=(385) Group A	Insulin n=(385) (Group B)	Test of Sig.
Age	24.92 ± 2.57 years	28.01 ± 2.53 years	t=-16.80 p=0.000
Gravidity	2.57 ± 1.17	2.35 ± 1.19	t=2.53 p=0.012
Parity	1.48 ± 0.66	1.41 ± 1.06	t=1.05 p=0.293
Gestational Age	27.94 ± 2.57 weeks	29.92 ± 2.27 weeks	t=-11.30 p=0.000
BMI in early pregnancy	22.08 ± 2.98 kg/m^2	23.82 ± 2.81 kg/m^2	t=-8.323 p=0.000
BMI during treatment	31.88 ± 2.26 kg/m^2	32.05 ± 1.89 kg/m^2	t=-1.10 p=0.271

Table No.2: Comparison between groups with respect to pattern of blood sugar level, maternal and neonatal complications and mode of delivery

Variable	Metformin n=(385) Group A	Insulin n=(385) (Group B)	Test of Sig.
FBS at entry	130.06 ± 10.34 mg/dl	122.37 ± 9.94 mg/dl	t=10.53 p=0.000
FBS after treatment	82.28 ± 5.51 mg/dl	76.88 ± 7.75 mg/dl	t=11.15 p=0.000
2hPPBS at entry	175.18 ± 7.89 mg/dl	174.46 ± 6.02 mg/dl	t=1.42 p=0.157
2hPPBS after treatment	111.94 ± 7.02 mg/dl	112.34 ± 5.02 mg/dl	t=-0.909 p=0.364
HbA1c at entry	5.73 ± 0.54 mg/dl	6.15 ± 0.59 mg/dl	t=-10.04 p=0.000
HbA1c after treatment	5.08 ± 0.42 mg/dl	5.71 ± 0.49 mg/dl	t=-19.11 p=0.000
Gestational HTN	7.3% (n=28)	8.1% (n=31)	$\chi^2=0.165$ p=0.684
Pre- eclampsia	4.4% (n=17)	15.6% (n=60)	$\chi^2=26.68$ P=0.000
Pre-term birth	2.6% (n=10)	12.5% (n=48)	$\chi^2=26.93$ P=0.000
Mode of delivery	CS 40.8% (n=157), NVD 59.2% (n=228)	CS 36.1% (n=139), NVD 63.9% (n=246)	$\chi^2=1.778$ P=0.182
Neonatal birth weight >4	10.9% (n=42)	18.7% (n=72)	$\chi^2=9.27$ P=0.002
Neonatal hypogly- cemia	28.3% (n=109)	52.5% (n=202)	$\chi^2=46.65$ P=0.000
Neonatal Jaundice	51.2% (n=197)	39.7% (n=153)	$\chi^2=10.14$ P=0.001

Gestational HTN 7.3% (n=28) and 8.1% (n=31), preeclampsia 4.4% (n=17) and 15.6% (n=60), pre-term birth 2.6% (n=10) and 12.5% (n=48), mode of delivery CS 40.8% (n=157), NVD 59.2% (n=228) and CS 36.1% (n=139), NVD 63.9% (n=246), neonatal birth weight >4 10.9% (n=42) and 18.7% (n=72), neonatal hypoglycemia 28.3% (n=109) and 52.5% (n=202), neonatal Jaundice 51.2% (n=197) and 39.7% (n=153), were noted for the group M and I respectively. (Table 2).

Significant difference was found between age (p=0.000), gravidity (p=0.012), gestational age (p=0.000), BMI in early pregnancy (p=0.000), FBS at entry (p=0.000), FBS after treatment (p=0.000), HbA1c at entry (p=0.000), HbA1c after treatment (p=0.000), in groups. Association was found between Preeclampsia (p=0.000), Pre-term birth (p=0.000), Neonatal birth weight >4 (p=0.002), neonatal hypoglycemia (p=0.000), in groups. (Table 2).

DISCUSSION

Prevalence of gestational diabetes varies within different races and it depends upon diagnostic tests used for its diagnosis. Use of a specific diagnostic criterion and a certain ethnic background suggests that gestational diabetes incidence varies from 2 to 8%¹³. Gestational diabetes has been reported to associate with many maternal and perinatal complications including, preeclampsia, macrosomia, shoulder dystocia, hypoglycemia, cesarean section, birth injuries and respiratory distress syndrome^{14,15}. Multiple studies have shown that risk of these complication rises with the rise in blood glucose level and that these complications can be prevented by proper management of hyperglycemia which is the major finding of gestational diabetes^{16, 17}. Recommendations regarding diagnosis and management of gestational diabetes are derived from American College of Obstetricians and Gynecologists and American Diabetes Association in attempt to avoid these unpleasant outcomes^{18,19}.

Women suffering from gestational diabetes who were unable to be treated with diet modifications and exercise recommendations are traditionally treated by insulin therapy²⁰. But insulin therapy carries risk of weight gain, difficulty for pregnant women as multiple injections are required daily and also there is risk of developing hypoglycemia. Therefore metformin is considered as a replacement therapy and it is also effective in gestational diabetes²¹. There are no risks of developing hypoglycemia and gaining of weight with use of metformin and metformin acts by preventing peripheral insulin resistance and diminishing gluconeogenesis in liver²².

According to a meta-analysis, there was no risk of major congenital anomalies associated with metformin. Other studies also gave the conclusion that oral hypoglycemic agents when compared with insulin are

not much different from insulin therapy in terms of maternal or neonatal outcomes, in women with gestational diabetes^{23,17}.

A study by Rai et al.²⁴ demonstrated that although insulin showed slightly better results, even then the difference was not statistically significant (p=0.08-0.69). In this study it was also found that adjusted glucose levels were significantly reduced in group of patients treated with metformin as compared to those treated with insulin (p=<0.001-0.003) after treating for one week. In other words metformin was uniform in controlling glucose level in comparison to insulin. But drawback of this particular prospective study was that sample size was not large enough.

Ija's H et al.²⁵ demonstrated that among the patients treated with metformin 32% required additional insulin to reach the normal blood glucose level. The observations suggest that women who needed additional insulin were mostly more obese, required earlier medical treatment and had higher fasting blood sugar levels as compared to the women who only required metformin to reach normal glucose levels. These findings suggest that these women had higher insulin resistance.

CONCLUSION

This study concludes that metformin is as much effective as insulin in management of gestational diabetes mellitus. Metformin when used securely can prove effective as it does not cause any congenital anomalies or maternal or neonatal complications. But insulin still remains the gold standard for treatment of gestational diabetes mellitus.

Author's Contribution:

Concept & Design of Study: Rao Muhammad Akram Khan
 Drafting: Ayesha Mukhtar, Anam Khawar
 Data Analysis: Ayesha Mukhtar
 Revisiting Critically: Rao Muhammad Akram Khan, Anam Khawar
 Final Approval of version: Rao Muhammad Akram Khan

Conflict of Interest: The study has no conflict of interest to declare by any author.

REFERENCES

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care 2014;37(Supplement 1):S81-90.
2. DeSisto CL, Kim SY, Sharma AJ. Peer Reviewed: Prevalence Estimates of Gestational Diabetes Mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. Preventing Chronic Dis 2014;11.
3. Ovesen PG, Jensen DM, Damm P, Rasmussen S, Kesmodel US. Maternal and neonatal outcomes in pregnancies complicated by gestational diabetes. A nation-wide study. J Maternal-Fetal Neonatal Med 2015;28(14):1720-4.
4. Mortier I, Blanc J, Tosello B, Gire C, Bretelle F, Carcopino X. Is gestational diabetes an independent risk factor of neonatal severe respiratory distress syndrome after 34 weeks of gestation? A prospective study. Archives of Gynecol Obstet 2017;1-7.
5. Tomar AS, Tallapragada DS, Nongmaithem SS, Shrestha S, Yajnik CS, Chandak GR. Intrauterine programming of diabetes and adiposity. Current Obesit Reports 2015;4(4):418-28.
6. Poomalar GK. Changing trends in management of gestational diabetes mellitus. World J Diabet 2015; 6(2):284.
7. Padayachee C, Coombes JS. Exercise guidelines for gestational diabetes mellitus. World J Diabet 2015;6(8):1033.
8. Magon N, Seshiah V. Gestational diabetes mellitus: insulinic management. J Obstet Gynecol Ind 2014;64(2):82-90.
9. Castillo WC, Boggess K, Stürmer T, Brookhart MA, Benjamin DK, Funk MJ. Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes. JAMA Pediatr 2015;169(5):452-8.
10. Copeland KC, Silverstein J, Moore KR, Pazar GE, Raymer T, Schiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatr 2013; 131(2):364-82.
11. Ryu RJ, Hays KE, Hebert MF. Gestational diabetes mellitus management with oral hypoglycemic agents. 38th ed. InSeminars in Perinatol: WB Saunders; 2014.p.508-515
12. Borg H, Ezat S. Metformin Opposed to Insulin in the Management of Gestational Diabetes. Res Obstet Gynecol 2016;4(2):17-26.
13. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;2008(358):1991-2002.
14. Contreras M, Sacks DA, Bowling FG, Cowley DM, Liley H, McIntyre HD, et al. HAPO Study Cooperative Research Group. The hyperglycemia and adverse pregnancy outcome (HAPO) study. Int J Gynecol Obstet 2002;78(1):69-77.
15. Homko CJ, Reece EA. Insulins and oral hypoglycemic agents in pregnancy. J Maternal-Fetal Neonatal Med 2006;19(11):679-86.
16. Rowan JA, Gao W, Hague WM, McIntyre HD. Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. Diabetes Care 2010;33(1):9-16.

17. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. *Obstet Gynecol* 2009;113(1):193-205.
18. American College of Obstetricians and Gynecologists. Gestational diabetes. ACOG practice bulletin no. 30. *Obstet Gynecol* 2001;98(3):525-38.
19. American Diabetes Association. The American Diabetes Association (ADA) has been actively involved in the development and dissemination of diabetes care standards, guidelines, and related documents for many years. Introduction. *Diabetes Care* 2009;32:S1.
20. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. *Best Practice Res Clin Obstet Gynaecol* 2011;25(1):51-63.
21. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. *Human Reproduction* 2004;19(3):510-21.
22. Wensel TM. Role of metformin in the treatment of gestational diabetes. *Annals of Pharmacotherapy* 2009;43(5):939-43.
23. Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. *Fertility and Sterility* 2006;86(3):658-63.
24. Rai L, Meenakshi D, Kamath A. Metformin-A convenient alternative to insulin for Indian women with diabetes in pregnancy, 2009.
25. Ijäs H, Vääräsmäki M, Morin Papunen L, Keravuo R, Ebeling T, Saarela T, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. *BJOG: An Int J Obstet Gynaecol* 2011;118(7):880-5.